Enterprise Value
0.00
Cash
8.535M
Avg Qtr Burn
N/A
Short % of Float
2.95%
Insider Ownership
38.69%
Institutional Own.
8.21%
Qtr Updated
09/30/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Batiraxcept (AVB-500) Details Renal cell carcinoma | Phase 3 Initiation | |
Batiraxcept (AVB-500) Details Pancreatic cancer | Failed Discontinued | |
Batiraxcept (AVB-500) Details Solid tumor/s, Cancer, Ovarian cancer | Failed Discontinued | |
Batiraxcept (AVB-500) Details Solid tumor/s, Cancer, Renal cell carcinoma | Failed Discontinued |